Cargando…
Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab()
SARS-CoV-2 is a new RNA virus which causes coronavirus disease 2019 (COVID-19), declared a pandemic by the World Health Organization (WHO). It triggers an atypical pneumonia that can progress to multiorgan failure. COVID-19 can cause dysregulation of the immune system, triggering an inflammatory res...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7561306/ https://www.ncbi.nlm.nih.gov/pubmed/34823820 http://dx.doi.org/10.1016/j.reumae.2020.06.008 |
_version_ | 1783595242341007360 |
---|---|
author | Figuero-Pérez, Luis Olivares-Hernández, Alejandro Escala-Cornejo, Roberto A. Terán-Brage, Eduardo López-Gutiérrez, Álvaro Cruz-Hernández, Juan J. |
author_facet | Figuero-Pérez, Luis Olivares-Hernández, Alejandro Escala-Cornejo, Roberto A. Terán-Brage, Eduardo López-Gutiérrez, Álvaro Cruz-Hernández, Juan J. |
author_sort | Figuero-Pérez, Luis |
collection | PubMed |
description | SARS-CoV-2 is a new RNA virus which causes coronavirus disease 2019 (COVID-19), declared a pandemic by the World Health Organization (WHO). It triggers an atypical pneumonia that can progress to multiorgan failure. COVID-19 can cause dysregulation of the immune system, triggering an inflammatory response, and simulate haemophagocytic lymphohistiocytosis. Several studies have proposed that anti-IL-6 receptor antibodies, such as tocilizumab, play an important role in the treatment of severe acute respiratory infection associated with SARS-CoV-2. However, the role of anti-IL-1 receptor antibodies, such as anakinra, in the treatment of COVID-19 has not been established. We present a case report of a 51-year-old man diagnosed with severe respiratory infection associated with SARS-CoV-2 that was refractory to antiviral and anti-IL-6 treatment, with a favourable clinical outcome and analytical improvement after treatment with anti-IL-1 (anakinra). |
format | Online Article Text |
id | pubmed-7561306 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75613062020-10-16 Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab() Figuero-Pérez, Luis Olivares-Hernández, Alejandro Escala-Cornejo, Roberto A. Terán-Brage, Eduardo López-Gutiérrez, Álvaro Cruz-Hernández, Juan J. Reumatol Clin (Engl Ed) Special Article SARS-CoV-2 is a new RNA virus which causes coronavirus disease 2019 (COVID-19), declared a pandemic by the World Health Organization (WHO). It triggers an atypical pneumonia that can progress to multiorgan failure. COVID-19 can cause dysregulation of the immune system, triggering an inflammatory response, and simulate haemophagocytic lymphohistiocytosis. Several studies have proposed that anti-IL-6 receptor antibodies, such as tocilizumab, play an important role in the treatment of severe acute respiratory infection associated with SARS-CoV-2. However, the role of anti-IL-1 receptor antibodies, such as anakinra, in the treatment of COVID-19 has not been established. We present a case report of a 51-year-old man diagnosed with severe respiratory infection associated with SARS-CoV-2 that was refractory to antiviral and anti-IL-6 treatment, with a favourable clinical outcome and analytical improvement after treatment with anti-IL-1 (anakinra). Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. 2021-12 2020-10-15 /pmc/articles/PMC7561306/ /pubmed/34823820 http://dx.doi.org/10.1016/j.reumae.2020.06.008 Text en © 2020 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Special Article Figuero-Pérez, Luis Olivares-Hernández, Alejandro Escala-Cornejo, Roberto A. Terán-Brage, Eduardo López-Gutiérrez, Álvaro Cruz-Hernández, Juan J. Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab() |
title | Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab() |
title_full | Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab() |
title_fullStr | Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab() |
title_full_unstemmed | Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab() |
title_short | Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab() |
title_sort | anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with sars-cov-2 refractory to tocilizumab() |
topic | Special Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7561306/ https://www.ncbi.nlm.nih.gov/pubmed/34823820 http://dx.doi.org/10.1016/j.reumae.2020.06.008 |
work_keys_str_mv | AT figueroperezluis anakinraasapotentialalternativeinthetreatmentofsevereacuterespiratoryinfectionassociatedwithsarscov2refractorytotocilizumab AT olivareshernandezalejandro anakinraasapotentialalternativeinthetreatmentofsevereacuterespiratoryinfectionassociatedwithsarscov2refractorytotocilizumab AT escalacornejorobertoa anakinraasapotentialalternativeinthetreatmentofsevereacuterespiratoryinfectionassociatedwithsarscov2refractorytotocilizumab AT teranbrageeduardo anakinraasapotentialalternativeinthetreatmentofsevereacuterespiratoryinfectionassociatedwithsarscov2refractorytotocilizumab AT lopezgutierrezalvaro anakinraasapotentialalternativeinthetreatmentofsevereacuterespiratoryinfectionassociatedwithsarscov2refractorytotocilizumab AT cruzhernandezjuanj anakinraasapotentialalternativeinthetreatmentofsevereacuterespiratoryinfectionassociatedwithsarscov2refractorytotocilizumab |